In a recent article from Pink Sheet, Nicolle Gatto (Chief Science Officer, Aetion) and Ulka Campbell (SVP, Head of Scientific Strategy) share their blueprint for integrating real-world data from preclinical through postmarketing phases. By embedding epidemiologists early, dedicating resources, and prioritizing foundational studies on treatment patterns and natural history, sponsors can avoid costly missteps and improve trial design and regulatory approval processes.